Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM5C | P41229 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL9508104 | 1.00 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL107799 | 1.00 | — | — | |
| Succinic Acid SCHEMBL29461603 | 0.97 | LMNA (0.56) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL27324587 | 0.97 | LMNA (0.56) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL30298887 | 0.94 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL155053 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL105373 | 0.93 | — | — | |
| Succinic Acid SCHEMBL18889846 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL151456 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL104934 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119656139-A | Andrographolide lung inhalation powder spray and preparation method thereof | 沈阳药科大学 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023134771-A1 | PHARMACEUTICAL COMPOSITION OF ANTI-CTLA-4 ANTIBODY AND USE THEREOF | 上海君实生物医药科技股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022222945-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY FUSION PROTEIN AND USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-112426410-B | Potassium dehydroandrographolide succinate enteric dry suspension | 黄山中皇制药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112315944-B | Preparation method of potassium dehydroandrographolide succinate enteric dry suspension | 黄山中皇制药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114437204-A | Method for purifying antibody or Fc fusion protein | 苏州盛迪亚生物医药有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022068914-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | 江苏恒瑞医药股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| EP-3939998-A1 | CD40 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021239134-A1 | LIPOSOME CONTAINING ETHYLENEDIAMINE TETRAACETIC ACID OR SALT THEREOF AND ERIBULIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 江苏恒瑞医药股份有限公司 | 2021-12-02 | — | — | WO | disclosed |
| CN-112618482-A | Novel protein formulations | 江苏恒瑞医药股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020063858-A1 | USE OF COMBINATION OF TLR AGONIST AND IMMUNE CHECKPOINT INHIBITOR IN PREPARATION OF DRUGS FOR TREATING TUMORS | 江苏恒瑞医药股份有限公司 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020043095-A1 | ANTI-TIM3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-03-05 | — | — | WO | disclosed |